Inventor · disambiguated record
Daniel Johannes Kowalewski
Also filed as: KOWALEWSKI DANIEL · KOWALEWSKI DANIEL JOHANNES
159 granted patents·77 pending applications·140 citations·filing 2015–2025
99Inventor score
Top patents by PatentIndex Score
236 records- 0199US10899810B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·6 cites·20 claims
- 0298US11732021B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 22, 2023·3 cites·20 claims
- 0398US11655281B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·3 cites·20 claims
- 0498US11655280B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·2 cites·20 claims
- 0598US11603397B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Mar 14, 2023·2 cites·20 claims
- 0698US11117941B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 14, 2021·3 cites·20 claims
- 0798US10899811B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·5 cites·20 claims
- 0898US10772915B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 15, 2020·5 cites·20 claims
- 0998US10695374B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·5 cites·26 claims
- 1097US11208449B2Peptides for use in immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 1197US10709738B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 14, 2020·3 cites·20 claims
- 1296US10286052B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted May 14, 2019·25 cites·17 claims
- 1396US10167317B1Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 1, 2019·6 cites·18 claims
- 1495US11020433B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 1, 2021·2 cites·20 claims
- 1595US10144763B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 4, 2018·5 cites·18 claims
- 1695US10064924B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Sep 4, 2018·24 cites·17 claims
- 1794US10000533B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Jun 19, 2018·5 cites·4 claims
- 1892US10364271B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 30, 2019·2 cites·23 claims
- 1992US2025092104A1Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2091US12318407B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Jun 3, 2025·0 cites·20 claims
- 2191US12290530B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted May 6, 2025·0 cites·20 claims
- 2291US12285443B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 29, 2025·0 cites·20 claims
- 2391US12274716B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
- 2491US12257269B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
- 2591US12246039B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 11, 2025·0 cites·20 claims
- 2691US10377797B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·13 cites·25 claims
- 2791US10196422B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 5, 2019·13 cites·16 claims
- 2891US2023285461A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2991US2023285462A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3090US11542303B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
- 3190US2024239865A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3290US2024166713A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3390US2024166717A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3490US2024239866A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3590US2024166715A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3690US2023241109A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3790US2024307447A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3890US2023241112A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3990US2023241113A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4090US2024269183A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4190US2024374642A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4290US2024358757A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4390US2024247045A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4490US2024166716A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4590US2023285460A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4690US2023241110A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4790US2023233612A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4890US2024239867A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4990US2023241108A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 5090US2023241114A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
Showing the top 50 of 236 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel Johannes Kowalewski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →